Why the study?
Poor response to antiplatelet agents increases thrombosis risk, making the selection of appropriate P2Y12 inhibitors by predicting high platelet reactivity an urgent challenge.
Answers are grounded in this paper and cite their sources.
This review outlines the advantages and drawbacks of genetic testing, platelet function testing, and risk scores in predicting high platelet reactivity to optimize P2Y12 inhibitor therapy.
Antiplatelet therapy is the foundational treatment for the prevention and treatment of coronary and cerebrovascular ischemic events in patients with coronary heart disease, ischemic stroke, and transient ischemic attack (TIA). However, with more and more studies reporting an increased risk of thrombosis in some patients due to poor response to therapeutic agents, the selection of appropriate P2Y12 inhibitors has become a major challenge that needs to be addressed urgently. Currently, commonly used oral P2Y12 inhibitors include clopidogrel, ticagrelor, and prasugrel. Assessing patients' risk factors before the development of treatment regimens by effectively predicting the risk of high platelet reactivity with specific P2Y12 inhibitors in advance to avert the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) is the key point to the problem. Up to now, methods available for predicting platelet reactivity include genetic testing, platelet function testing, and risk scores. This review provides a summarization of the existent available identification methods and analyzes the advantages and drawbacks of different methods in specific clinical settings, intending to guide the rational clinical application of P2Y12 receptor inhibitors.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: